Universität zu Köln

Chemnitz, Jens Marcus, Uener, Jens, Hallek, Michael and Scheid, Christof (2010). Long-term follow-up of idiopathic thrombotic thrombocytopenic purpura treated with rituximab. Ann. Hematol., 89 (10). S. 1029 - 1034. NEW YORK: SPRINGER. ISSN 0939-5555

Full text not available from this repository.

Abstract

Rituximab may be used to treat patients with thrombotic thrombocytopenic purpura (TTP) refractory to plasma exchange or recurrent disease. While initial response rates are reported to be high, long-term follow-up data of patients treated with rituximab are not available to date, however important to estimate the safety and benefit of this treatment. Twelve patients with non-familial idiopathic TTP refractory to plasma exchange or with recurrent disease treated with rituximab between 2000 and 2008 were reexamined. The median follow-up was 49.6 months, ranging from 11 to 97 months. All patients achieved initial complete remission after application of rituximab. During follow-up, nine patients remained disease-free and three patients suffered from recurrent disease. All patients with recurrent disease responded to subsequent rituximab therapy. No long-term side effects were noted during the follow-up period. In conclusion, rituximab represents an effective second-line treatment option in relapsing or refractory TTP. Still, patients need to be closely monitored for relapses with extended follow-up.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Chemnitz, Jens Marcus UNSPECIFIED UNSPECIFIED UNSPECIFIED Uener, Jens UNSPECIFIED UNSPECIFIED UNSPECIFIED Hallek, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED Scheid, Christof UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-494537
DOI:	10.1007/s00277-010-0968-3
Journal or Publication Title:	Ann. Hematol.
Volume:	89
Number:	10
Page Range:	S. 1029 - 1034
Date:	2010
Publisher:	SPRINGER
Place of Publication:	NEW YORK
ISSN:	0939-5555
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language VON-WILLEBRAND-FACTOR; HEMOLYTIC-UREMIC SYNDROME; FACTOR-CLEAVING PROTEASE; ANTIBODIES; DISORDERS; ADAMTS13; SURVIVAL; THERAPY Multiple languages Hematology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/49453